Nabota, Botulax and Hutox: How Korean Botulinum Toxin Brands Differ

Korean botulinum toxin brands — mainly Nabota, Botulax and Hutox — are botulinum toxin type A products made by Korean pharmaceutical companies and used in Korean clinics in place of Allergan's Botox.

For an international patient this matters in two ways. The price quoted for a wrinkle-relaxing session in Seoul often reflects which product is in the vial, and the number of units quoted cannot be compared across brands the way currency can be converted. This guide sets out who manufactures each product, what regulators have actually approved and where, what the published evidence does and does not establish, and the questions worth asking before anything is injected. Where a fact could not be confirmed against a primary regulatory source, that is said plainly rather than smoothed over.

Who Makes Each Product

Nabota is made by Daewoong Pharmaceutical. Outside Korea the same active substance is sold in the United States under the trade name Jeuveau (prabotulinumtoxinA-xvfs), distributed by Evolus, which the US Food and Drug Administration approved in February 2019 for moderate to severe glabellar lines. A patient who has heard of Jeuveau but not Nabota is, in substance, looking at the same toxin lineage.

Botulax is made by Hugel. Hugel's US-approved product carries a different trade name, Letybo, approved by the FDA in March 2024 in 50-unit and 100-unit vials. Whether Letybo and Botulax are identical formulations or separate regulatory dossiers could not be confirmed from primary documents for this article, so they are best treated as related but not proven interchangeable. Hutox is made by Huons Biopharma; it holds export approvals in some markets, but no US approval was identified and no primary Korean approval date could be confirmed.

What Regulators Have Actually Approved

The gap between what a product is licensed for and what a clinic offers it for is wider than most marketing suggests. Jeuveau's FDA approval covers glabellar lines — the vertical frown lines between the eyebrows — in adults, and nothing further. Korean clinics routinely offer the same toxin family for forehead lines, crow's feet, masseter slimming, underarm sweating and calf contouring. Some of those uses may sit within Korean Ministry of Food and Drug Safety labelling, but this article could not verify the label text for each indication.

The point is not that off-label injection is improper; prescribing an approved drug outside its labelled indication is lawful and commonplace in many countries. The point is that the word approved is doing less work in a clinic brochure than a patient may assume, and it is reasonable to ask which indication the product is licensed for in Korea and whether your intended treatment falls inside it.

The Unit Problem: Why 20 Units Is Not a Fixed Quantity

This is the most consequential technical fact in the article. Potency units for botulinum toxin are defined by each manufacturer's own assay. They are not a shared international measure, and regulators have warned against using units to compare dosing between different toxin products. The peer-reviewed review most often cited on this point — Brin and James in Biologics: Targets and Therapy, 2014 — concluded that unit labelling is manufacturer-specific and that type A products are not interchangeable. That review examined Botox, Dysport and Xeomin rather than the Korean brands, so extending its conclusion to Nabota, Botulax or Hutox is a reasonable inference rather than a demonstrated equivalence.

What follows practically: a quote of fifty units for the masseter tells you very little until you know the product. Comparing two clinics on unit count alone, or asking a second clinic to match the dose a first clinic used with a different brand, may produce a different biological effect than intended. Ask for the product name and the unit count together, and keep a written record of both.

What Has Actually Been Tested Head-to-Head

Nabota has been compared directly with Botox. A phase III non-inferiority study comparing prabotulinumtoxinA with onabotulinumtoxinA for glabellar lines is indexed in PubMed from 2019, with a post-hoc analysis published in 2022 and a split-face onset comparison in 2023. That is a genuine head-to-head evidence base, although all three are now more than twelve months old and are better read as established than as current.

For Botulax and Hutox, no head-to-head non-inferiority trial against Botox could be verified for this article. A 2024 phase 3 active-controlled trial in the Journal of Dermatological Treatment compared two botulinum toxin type A formulations in Asian patients for glabellar lines, but the specific brands compared could not be confirmed. Absence of a verified trial is not evidence of inferiority; it means a comparative claim a clinic makes about those two products may rest on manufacturer data rather than independent head-to-head publication.

Duration and Realistic Retreatment Intervals

Across the botulinum toxin type A class, most approved products are studied with a retreatment interval in the region of twelve to sixteen weeks — roughly three to four months. Individual duration varies with dose, muscle mass, injection technique, metabolism and how expressive the treated area is. Durations reported in the literature are ranges, not commitments, and should be read that way.

Two patterns are worth setting expectations against. Large, strong muscles treated for contouring rather than for lines — the masseter is the common example — often show slower onset and a longer apparent effect than glabellar injection, because part of the visible outcome is gradual muscle volume reduction over months. And a first treatment sometimes appears to fade faster than later ones. Neither pattern justifies a clinic stating a fixed duration in weeks; a clinic that does is claiming more than the evidence supports.

Regulatory and Legal History Worth Knowing

Korean toxin manufacturers have been through substantial litigation, and a patient reading older coverage may encounter alarming headlines whose outcomes were later reversed. In November 2021 the Ministry of Food and Drug Safety announced revocation of licences for four Botulax products over national shipping approval; a Seoul court suspended that order by injunction the following day, and in February 2024 the Seoul Administrative Court ruled in Hugel's favour and cancelled the revocation and recall order while upholding earlier cease-and-desist and sales-suspension orders.

Separately, a trade-secret dispute between Medytox and Daewoong led the US International Trade Commission to rule in December 2020 that Daewoong had misappropriated toxin-strain trade secrets, with an import ban resolved by a licensing settlement announced in February 2021 that allowed continued US sale of Jeuveau. In a related matter concerning Medytox's own Meditoxin, the Korean Supreme Court upheld a ruling against the regulator's revocation in March 2025. None of this indicates which product a patient should choose. It does explain why brand availability in Korea has shifted over recent years.

Counterfeit and Unlicensed Toxin: Where the Real Risk Sits

For most international patients the meaningful safety question is not which licensed Korean brand is used, but whether the product is licensed at all and who injects it. In November 2025 the FDA issued a warning letter to a seller marketing Nabota 200ui online as an unapproved and misbranded drug with unapproved claims, and stated that products from unapproved sources may be contaminated, counterfeit, contain varying amounts of active ingredient, or contain different ingredients altogether. A separate multi-state cluster of botulism-like illness in the United States in 2024 was linked to counterfeit injections labelled as Botox, not to any Korean brand specifically.

Treatment at a licensed Korean clinic by a licensed physician, using a product with Korean regulatory approval, is a materially different situation from vials bought online or injection in a non-clinical setting. Toxin obtained outside the regulated supply chain carries risks that injector skill does not offset.

What to Ask Before Anything Is Injected

A short, specific set of questions tends to separate a clinic that will give you a straight answer from one that will not. None of these questions is unusual or impolite in a Korean clinic accustomed to international patients, and a coordinator can relay them if there is a language gap.

A pre-injection checklist

Which product, by brand name, will be used, and which company makes it. How many units of that specific product, and in which areas. Whether the product holds Korean approval for the indication being treated, or whether the use is off-label. Whether the vial will be opened and reconstituted in your presence. Who will perform the injection, and whether that person is a licensed physician. What the clinic's protocol is if you develop eyelid droop, asymmetry or a weaker result than expected, and whether review or correction is included in the quoted price. Finally, ask for the product name and unit count in writing, so that a clinic in another country has something meaningful to work from later.

Is Botulax the same as Botox?

No. Both are botulinum toxin type A, but they are different products from different manufacturers — Botulax from Hugel, Botox from Allergan and AbbVie — with separately defined potency units. They should not be treated as unit-for-unit equivalents, and no verified head-to-head non-inferiority trial of Botulax against Botox was identified for this article.

Are Korean toxin brands less safe than Botox?

Being manufactured in Korea does not by itself indicate lower safety. What matters is whether the specific product holds regulatory approval where it is used, whether it reached the clinic through the legitimate supply chain, and who performs the injection. Nabota has published head-to-head data against Botox; Botulax and Hutox have less verifiable independent comparative evidence, which is a gap in the published record rather than a demonstrated safety problem.

Why is toxin treatment cheaper in Korea?

Domestic manufacturing competition, high procedure volume and clinic density all contribute. A lower price does not reliably signal a lower-grade product, and a higher price does not reliably signal that Botox is being used. Ask which product is in the vial rather than inferring it from the quote.

Can I ask for a specific brand?

Usually yes, and it is reasonable to do so, although a clinic may stock only certain products and the price may differ by brand. If you have had a satisfactory result with a specific product elsewhere, name it and bring the unit count, since matching a dose across brands is not a simple conversion.

How soon before flying home should I be treated?

Toxin injection is minimally invasive and does not usually carry the flight-timing constraints of surgery, but onset takes several days, and any asymmetry that needs a small correction generally becomes apparent within about two weeks. Scheduling treatment early enough in your trip to allow a review visit, or agreeing in advance how a remote follow-up would work, is more useful than treating on your final day.

Before You Book

If you are comparing clinics or quotes for wrinkle-relaxing treatment in Korea, the two details that make the comparison meaningful are the product's brand name and the unit count for that product — not the unit count alone. Bring both to every consultation, and ask any clinic unwilling to supply them why that is. Nothing in this article is medical advice for an individual case; only a licensed physician who has examined you can say whether toxin treatment is appropriate for you.

Sources consulted include the US Food and Drug Administration, the Korean Ministry of Food and Drug Safety, Biologics: Targets and Therapy, the Journal of Dermatological Treatment and PubMed-indexed clinical trial reports.